MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Autor: Venner, Christopher P., Leblanc, Richard, Sandhu, Irwindeep, White, Darrell J., Belch, Andrew R, Reece, Donna E, Chen, Christine I, Dolan, Sean, Kew, Andrea, Lalancette, Marc, Louzada, Martha L, McCurdy, Arleigh, McDonald, Gail T., Reiman, Tony, Rodriguez, Laura, Shepherd, Lois E., Gul, Engin, Chen, Bingshu E., Hay, Annette E
Zdroj: Blood; November 2018, Vol. 132 Issue: Supplement 1 p1984-1984, 1p
Abstrakt: Venner: Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria; Takeda: Honoraria. Leblanc:Celgene Canada: Membership on an entity's Board of Directors or advisory committees; Janssen Inc.: Membership on an entity's Board of Directors or advisory committees; Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Takeda Canada: Membership on an entity's Board of Directors or advisory committees. Sandhu:Celgene: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Novartis: Honoraria; Bioverativ: Honoraria. White:Amgen, Celgene, Janssen, Takeda: Honoraria. Chen:Amgen: Honoraria. Louzada:Celgene: Honoraria; Janssen: Honoraria; amgen: Honoraria; pfizer: Honoraria. Hay:Amgen: Research Funding; Novartis: Research Funding; Janssen: Research Funding; Roche: Research Funding; Seattle Genetics: Research Funding; Kite: Research Funding.
Databáze: Supplemental Index